Cobas® 4800 HPV Test, a real-time polymerase chain reaction assay for the detection of human papillomavirus in cervical specimens

Expert Review of Molecular Diagnostics

Volumn 14, Issue 1, 2014, Pages 5-16

  Isidean, Sandra D ^a   Coutlée, François ^a,b   Franco, Eduardo L ^a  

^a MCGILL UNIVERSITY   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Cervical cancer; Cobas 4800 HPV Test; Diagnostic test; Genotyping; HPV DNA; HPV testing; Human papillomavirus; PCR; Screening

Indexed keywords

ARTICLE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 66; HUMAN PAPILLOMAVIRUS TYPE 68; HUMAN PAPILLOMAVIRUS TYPE 70; HUMAN PAPILLOMAVIRUS TYPE 73; HUMAN PAPILLOMAVIRUS TYPE 82; NONHUMAN; PAPILLOMAVIRUS INFECTION; REAL TIME POLYMERASE CHAIN REACTION; UTERINE CERVIX CANCER; VIRUS TYPING; WART VIRUS; EARLY DIAGNOSIS; FEMALE; GENETICS; GENOTYPING TECHNIQUE; MOLECULAR DIAGNOSIS; PATHOLOGY; SENSITIVITY AND SPECIFICITY; STANDARD; UTERINE CERVIX; UTERINE CERVIX TUMOR; VIROLOGY;

VIRUS DNA;

CERVIX UTERI; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; GENOTYPING TECHNIQUES; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRUS INFECTIONS; REAL-TIME POLYMERASE CHAIN REACTION; REFERENCE STANDARDS; SENSITIVITY AND SPECIFICITY; UTERINE CERVICAL NEOPLASMS;

EID: 84893032703     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2014.865521     Document Type: Article

References (61)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127(12), 2893-2917 (2010
2. Walboomers JM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189(1), 12-19 (1999
3. De Villiers EM. Cross-roads in the classification of papillomaviruses. Virology 445(1-2), 2-10 (2013
4. Smith JS, Lindsay L, Hoots B et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-Analysis update. Int. J. Cancer 121(3), 621-632 (2007
5. De Sanjose S, Quint WG, Alemany L et al. Human papillomavirus genotype attribution in invasive cervical cancer: A retrospective cross-sectional worldwide study. Lancet Oncol. 11(11), 1048-1056 (2010
6. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 62(1), 10-29 (2012
7. Arbyn M, Ronco G, Anttila A et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 30(Suppl. 5), F88-F99 (2012
8. Nanda K, Mccrory DC, Myers ER et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: A systematic review. Ann. Intern. Med. 132(10), 810-819 (2000
9. Stoler MH, Schiffman M, Atypical Squamous Cells of Undetermined Significance-Low-Grade Squamous Intraepithelial Lesion Triage Study Group. Interobserver reproducibility of cervical cytologic and histologic interpretations: Realistic estimates from the ASCUS-LSIL Triage Study. JAMA 285(11), 1500-1505 (2001
10. Franco EL. Chapter 13: Primary screening of cervical cancer with human papillomavirus tests. J. Natl Cancer Inst. Monogr. (31), 89-96 (2003
11. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J. Clin. Virol. 32(Suppl. 1), S16-S24 (2005
12. Bruni L, Diaz M, Castellsague X, Ferrer E, Bosch FX, De Sanjose S. Cervical human papillomavirus prevalence in 5 continents: Meta-Analysis of 1 million women with normal cytological findings. J. Infect. Dis. 202(12), 1789-1799 (2010
13. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 370(9590), 890-907 (2007
14. Khan MJ, Castle PE, Lorincz AT et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl Cancer Inst. 97(14), 1072-1079 (2005
15. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: Clinical applications of HPV testing: A summary of meta-Analyses. Vaccine 24 (Suppl. 3), S3/78-89 (2006
16. Saslow D, Solomon D, Lawson HW et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J. Clin. 62(3), 147-172 (2012
17. Moyer VA, Force USPST. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 156(12), 880-891, W312 (2012
18. Canadian Task Force on Preventive Health C, Pollock S, Dunfield L et al. Recommendations on screening for cervical cancer. CMAJ 185(1), 35-45 (2013
19. Murphy J, Kennedy EB, Dunn S et al. Cervical screening: A guideline for clinical practice in Ontario. J. Obstet. Gynaecol. Can. 34(5), 453-458 (2012
20. Arbyn M, Anttila A, Jordan J et al. European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition-summary document. Ann. Oncol. 21(3), 448-458 (2010
21. Castle PE, De Sanjose S, Qiao YL, Belinson JL, Lazcano-Ponce E, Kinney W. Introduction of human papillomavirus DNA screening in the world: 15 years of experience. Vaccine 30(Suppl. 5), F117-F122 (2012
22. Zappacosta R, Caraceni D, Ciccocioppo L et al. Implementing specificity of HPV-DNA primary screening in a successful organised cervical cancer prevention programme. Gynecol. Oncol. 128(3), 427-432 (2013
23. Snijders PJ, Heideman DA, Meijer CJ. Methods for HPV detection in exfoliated cell and tissue specimens. APMIS 118(6-7), 520-528 (2010
24. Poljak M, Cuzick J, Kocjan BJ, Iftner T, Dillner J, Arbyn M. Nucleic acid tests for the detection of alpha human papillomaviruses. Vaccine 30(Suppl. 5), F100-F106 (2012
25. Poljak M, Kocjan BJ. Commercially available assays for multiplex detection of alpha human papillomaviruses. Expert Rev. Anti Infect. Ther. 8(10), 1139-1162 (2010
26. Meijer CJ, Berkhof J, Castle PE et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int. J. Cancer 124(3), 516-520 (2009
27. Meijer CJ, Snijders PJ, Castle PE. Clinical utility of HPV genotyping. Gynecol. Oncol. 103(1), 12-17 (2006
28. Cuzick J, Bergeron C, Von Knebel Doeberitz M et al. New technologies and procedures for cervical cancer screening. Vaccine 30(Suppl. 5), F107-F116 (2012
29. Preisler S, Rebolj M, Untermann A et al. Prevalence of human papillomavirus in 5,072 consecutive cervical SurePath samples evaluated with the Roche cobas HPV real-Time PCR assay. PLoS ONE 8(3), e59765 (2013
30. Gilbert L, Oates E, Ratnam S. Stability of cervical specimens in surepath medium for HPV Testing with Roche cobas (R) 4800. J. Clin. Microbiol. 51(10), 3412-3414 (2013
31. Rao A, Young S, Erlich H et al. Development and characterization of the cobas human papillomavirus test. J. Clin. Microbiol. 51(5), 1478-1484 (2013
32. Castle PE, Sadorra M, Lau T, Aldrich C, Garcia FA, Kornegay J. Evaluation of a prototype real-Time PCR assay for carcinogenic human papillomavirus (HPV) detection and simultaneous HPV genotype 16 (HPV16) and HPV18 genotyping. J. Clin. Microbiol. 47(10), 3344-3347 (2009
33. Castle PE, Stoler MH, Wright TC Jr, Sharma A, Wright TL, Behrens CM. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: A subanalysis of the ATHENA study. Lancet Oncol. 12(9), 880-890 (2011
34. Stoler MH, Wright TC Jr, Sharma A et al. High-risk human papillomavirus testing in women with ASC-US cytology: Results from the ATHENA HPV study. Am. J. Clin. Pathol. 135(3), 468-475 (2011
35. Wright TC, Jr., Stoler MH, Sharma A et al. Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV+ cytology-negative results. Am. J. Clin. Pathol. 136(4), 578-586 (2011
36. Wright TC, Castle PE, Behrens CM, Huh WK. Risk of ‡CIN3 after 3 years of follow-up of 42,209 screened women: End of study results from ATHENA. SGO LBA1 (2013
37. Heideman DA, Hesselink AT, Berkhof J et al. Clinical validation of the cobas 4800 HPV test for cervical screening purposes. J. Clin. Microbiol. 49(11), 3983-3985 (2011
38. Lloveras B, Gomez S, Alameda F et al. HPV testing by cobas HPV test in a population from Catalonia. PLoS ONE 8(3), e58153 (2013
39. Gage JC, Sadorra M, Lamere BJ et al. Comparison of the cobas Human Papillomavirus (HPV) test with the hybrid capture 2 and linear array HPV DNA tests. J. Clin. Microbiol. 50(1), 61-65 (2012
40. Mateos ML, Chacon De Antonio J, Rodriguez-Dominguez M, Sanz I, Rubio MD. [Evaluation of a prototype real-Time PCR assay for the separate detection of human papilloma virus genotypes 16 and 18 and other high risk human papillomavirus in cervical cancer screening]. Enferm. Infecc. Microbiol. Clin. 29(6), 411-414 (2011
41. Lindemann ML, Dominguez MJ, De Antonio JC et al. Analytical comparison of the cobas HPV Test with Hybrid Capture 2 for the detection of high-risk HPV genotypes. J. Mol. Diagn. 14(1), 65-70 (2012
42. Ki EY, Kim HE, Choi YJ, Park JS, Kang CS, Lee A. Comparison of the Cobas 4800 HPV test and the Seeplex HPV4A ACE with the hybrid capture 2 test. Int. J. Med. Sci. 10(2), 119-123 (2013
43. Wong AA, Fuller J, Pabbaraju K, Wong S, Zahariadis G. Comparison of the hybrid capture 2 and cobas 4800 tests for detection of high-risk human papillomavirus in specimens collected in PreservCyt medium. J. Clin. Microbiol. 50(1), 25-29 (2012
44. Lapierre SG, Sauthier P, Mayrand MH et al. Human papillomavirus (HPV) DNA triage of women with atypical squamous cells of undetermined significance with cobas 4800 HPV and Hybrid Capture 2 tests for detection of high-grade lesions of the uterine cervix. J. Clin. Microbiol. 50(4), 1240-1244 (2012
45. Martinez SB, Palomares JC, Artura A et al. Comparison of the Cobas 4800 Human Papillomavirus test against a combination of the Amplicor Human Papillomavirus and the Linear Array tests for detection of HPV types 16 and 18 in cervical samples. J. Virol. Methods 180(1-2), 7-10 (2012
46. Park Y, Lee E, Choi J, Jeong S, Kim HS. Comparison of the Abbott RealTime High-Risk Human Papillomavirus (HPV), Roche Cobas HPV, and Hybrid Capture 2 assays to direct sequencing and genotyping of HPV DNA. J. Clin. Microbiol. 50(7), 2359-2365 (2012
47. Szarewski A, Mesher D, Cadman L et al. Comparison of seven tests for high-grade cervical intraepithelial neoplasia in women with abnormal smears: The Predictors 2 study. J. Clin. Microbiol. 50(6), 1867-1873 (2012
48. Cuzick J, Cadman L, Mesher D et al. Comparing the performance of six human papillomavirus tests in a screening population. Br. J. Cancer 108(4), 908-913 (2013
49. Kjaer SK, Frederiksen K, Munk C, Iftner T. Long-Term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: Role of persistence. J. Natl Cancer Inst. 102(19), 1478-1488 (2010
50. Castle PE, Solomon D, Schiffman M, Wheeler CM. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J. Natl Cancer Inst. 97(14), 1066-1071 (2005
51. Cox JT, Castle PE, Behrens CM et al. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: Results from the ATHENA HPV study. Am. J Obstet. Gynecol. 208(3), 184 e181-184 e111 (2013
52. Cuzick J, Thomas Cox J, Zhang G et al. Human papillomavirus testing for triage of women with low-grade squamous intraepithelial lesions. Int. J. Cancer 132(4), 959-966 (2013
53. Vijayaraghavan A, Efrusy MB, Mayrand MH, Santas CC, Goggin P. Cost-effectiveness of high-risk human papillomavirus testing for cervical cancer screening in Quebec, Canada. Can. J. Public Health 101(3), 220-225 (2010
54. Vijayaraghavan A, Efrusy MB, Goodman KA, Santas CC, Huh WK. Cost-effectiveness of using human papillomavirus 16/18 genotype triage in cervical cancer screening. Gynecol. Oncol. 119(2), 237-242 (2010
55. De Kok IM, Van Rosmalen J, Dillner J et al. Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: Cost effectiveness analysis based on a Dutch microsimulation model. BMJ 344, e670 (2012
56. Burger EA, Ortendahl JD, Sy S, Kristiansen IS, Kim JJ. Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway. Br. J. Cancer 106(9), 1571-1578 (2012
57. Sroczynski G, Schnell-Inderst P, Muhlberger N et al. Cost-effectiveness of primary HPV screening for cervical cancer in Germany-A decision analysis. Eur. J. Cancer 47(11), 1633-1646 (2011
58. Ogilvie GS, Krajden M, Van Niekerk DJ et al. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: Results of round 1 of a randomised controlled trial-The HPV FOCAL Study. Br. J. Cancer 107(12), 1917-1924 (2012
59. Leinonen M, Nieminen P, Kotaniemi-Talonen L et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J. Natl Cancer Inst. 101(23), 1612-1623 (2009
60. Franco EL, Cuzick J, Hildesheim A, De Sanjose S. Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 24(Suppl. 3), S3/171-177 (2006
61. A review of human carcinogens. Part B: Biological agents/IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. WHO Press, Lyon, France (2009